Literature DB >> 12588007

Smallpox Vaccine Adverse Events Monitoring and Response System for the first stage of the smallpox vaccination program.

.   

Abstract

Smallpox vaccination of civilian volunteer health-care workers began on January 24, 2003. As of February 4, a total of 37 states and counties have received shipments of smallpox vaccine, and 18 states and counties have begun smallpox vaccination; no serious adverse events have been reported. To monitor the occurrence of adverse events associated with vaccination, both those expected on the basis of previous experience and possible new unexpected adverse events, CDC and state health departments have established the Smallpox Vaccine Adverse Events Monitoring and Response System. The system also will be used to monitor the effectiveness of contraindication screening, identify new contraindications, and coordinate the distribution of vaccinia immune globulin (VIG) and cidofovir to the civilian population. This notice describes the components of the system, delineates roles and responsibilities, and explains how data from the system will be compiled and communicated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12588007

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  6 in total

1.  Antimicrobial activity of community-associated methicillin-resistant Staphylococcus aureus is caused by phenol-soluble modulin derivatives.

Authors:  Hwang-Soo Joo; Gordon Y C Cheung; Michael Otto
Journal:  J Biol Chem       Date:  2011-01-28       Impact factor: 5.157

Review 2.  [Methicillin-resistant Staphylococcus aureus. Types of resistance and clinical consequences].

Authors:  U Geipel; M Herrmann
Journal:  Anaesthesist       Date:  2005-02       Impact factor: 1.041

3.  Staphylococcus aureus colonization in a community sample of HIV-infected and HIV-uninfected drug users.

Authors:  M Miller; C Cespedes; P Vavagiakis; R S Klein; F D Lowy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-18       Impact factor: 3.267

4.  Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.

Authors:  Sophie Duraffour; Robert Snoeck; Marcela Krecmerová; Joost van Den Oord; Rita De Vos; Antonín Holy; Jean-Marc Crance; Daniel Garin; Erik De Clercq; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

Review 5.  Data mining in the US using the Vaccine Adverse Event Reporting System.

Authors:  John Iskander; Vitali Pool; Weigong Zhou; Roseanne English-Bullard
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

Review 6.  Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000(®) compared with Dryvax(®).

Authors:  Danielle M Tack; Kevin L Karem; Jay R Montgomery; Limone Collins; Marthe G Bryant-Genevier; Rosemary Tiernan; Maria Cano; Paige Lewis; Renata J M Engler; Inger K Damon; Mary G Reynolds
Journal:  Hum Vaccin Immunother       Date:  2013-04-09       Impact factor: 4.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.